Siyuan Le News Today : Breaking News, Live Updates & Top Stories | Vimarsana

GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies

A new research paper was published in Oncotarget's Volume 14 on December 20, 2023, entitled, "The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies."

Qiang luLili tangFubo xieSiyuan leFusheng zhouJinmin renDragan cicicGenfleet therapeutics incSellas life sciences groupJiong lanGenfleet therapeuticsCell cycleN vivoProtein expression

GFH009: Potent, Selective CDK9 Inhibitor for Hematologic Cancer

GFH009: Potent, Selective CDK9 Inhibitor for Hematologic Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

Jinmin renDragan cicicLili tangFubo xieFusheng zhouQiang luSiyuan leSellas life sciences groupGenfleet therapeutics incOncotarget volumeJiong lanGenfleet therapeutics

SELLAS Life Sciences to Present Data on its Highly Selective CDK9 Inhibitor, GFH009, at the 2022 American Society of Hematology (ASH) Annual Meeting

03.11.2022 - NEW YORK, Nov. 03, 2022 (GLOBE NEWSWIRE) - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer . Seite 1

Dragan cicicSiyuan leErnestn morial convention centerClinical developmentExperimental therapeuticsConvention centerSenior vice presidentProspective therapeutic trials